Support and Resistance Basics
What is MACD and how to read it?
How RSI can help?
Stock Summary
Top Correlated Resources
HCAT
Top 10 Correlated Stocks
HCAT
In the News
Health Catalyst to Participate in Upcoming Investor Conference
SALT LAKE CITY, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced that Bryan Hunt, Chief Financial Officer, and Adam Brown, Senior Vice President of Investor Relations and FP&A, will participate in the Canaccord Genuity 42nd Annual Growth Conference, being held in Boston on Thursday, August 11, 2022, including a fireside chat presentation at 12:00pm ET. The replay of the presentation will be available online at https://ir.healthcatalyst.com.
Health Catalyst, Inc. (HCAT) CEO Dan Burton on Q2 2022 Results - Earnings Call Transcript
Health Catalyst, Inc. (NASDAQ:HCAT ) Q2 2022 Earnings Conference Call August 4, 2022 5:00 PM ET Company Participants Adam Brown – Senior Vice President-Finance and Investor Relations Dan Burton – Chief Executive Officer Bryan Hunt – Chief Financial Officer Conference Call Participants Anne Samuel – J.P. Morgan Jared Haase – William Blair Elizabeth Anderson – Evercore Stephanie Davis – SVB Securities John Ransom – Raymond James Jessica Tassan – Piper Sandler Richard Close – Canaccord Genuity Daniel Grosslight – Citi Rohan Chandrasekhar – Guggenheim Partners Operator Good day, ladies and gentlemen, and thank you for standing by.
Health Catalyst (HCAT) Reports Q2 Loss, Tops Revenue Estimates
Health Catalyst (HCAT) delivered earnings and revenue surprises of 72.73% and 1.23%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
7 Small-Cap Growth Stocks Trading at a Huge Discount Right Now
When equities are under pressure, it is particularly important for investors to find stocks that are trading at a discount to their intrinsic value. This can be particularly difficult if you're interested in finding small-cap growth stocks trading at a discount.
Health Catalyst to Announce Second Quarter 2022 Operating Results and Host Conference Call on Thursday, August 4, 2022
SALT LAKE CITY, July 21, 2022 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, will release its second quarter 2022 operating results on Thursday, August 4, 2022, after market close. In conjunction, the company will host a conference call to review the results at 5 p.m. E.T. on the same day.
Health Catalyst to Participate in Upcoming Investor Conferences
SALT LAKE CITY, June 01, 2022 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced that Bryan Hunt, Chief Financial Officer, and Adam Brown, Senior Vice President of Investor Relations and FP&A, will participate in the following upcoming investor conferences:
Health Catalyst, Inc. (HCAT) CEO Dan Burton on Q1 2022 Results - Earnings Call Transcript
Health Catalyst, Inc. (NASDAQ:HCAT ) Q1 2022 Earnings Conference Call May 10, 2022 5:00 PM ET Company Participants Adam Brown - IR Dan Burton - CEO Bryan Hunt - CFO Conference Call Participants Anne Samuel - JPMorgan Ryan Daniels - William Blair Jessica Tassan - Piper Sandler Cindy Motz - Goldman Sachs Elizabeth Anderson - Evercore Stephanie Davis - SVB Securities Richard Close - Canaccord Genuity John Ransom - Raymond James Daniel Grosslight - Citi David Larsen - BTIG Dev Weerasuriya - Berenberg Operator Good day, and thank you for standing by. Welcome to the Health Catalyst First Quarter 2022 Earnings Conference Call.
Health Catalyst (HCAT) Reports Q1 Loss, Tops Revenue Estimates
Health Catalyst (HCAT) delivered earnings and revenue surprises of 25% and 3.35%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Health Catalyst to Announce First Quarter 2022 Operating Results and Host Conference Call on Tuesday, May 10, 2022
SALT LAKE CITY, April 26, 2022 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, will release its first quarter 2022 operating results on Tuesday, May 10, 2022, after market close. In conjunction, the company will host a conference call to review the results at 5 p.m. E.T. on the same day.
Health Catalyst, Inc. (HCAT) CEO Dan Burton on Q4 2021 Results - Earnings Call Transcript
Health Catalyst, Inc. (HCAT) CEO Dan Burton on Q4 2021 Results - Earnings Call Transcript
Financial details
Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Revenue per share | 8.27 | 4.78 | 5.09 | |
| Net income per share | -3.21 | -2.91 | -3.23 | |
| Operating cash flow per share | -1.72 | -0.66 | -0.49 | |
| Free cash flow per share | -1.95 | -0.86 | -0.85 | |
| Cash per share | 12.18 | 6.85 | 9.37 | |
| Book value per share | 10.71 | 6.98 | 10.99 | |
| Tangible book value per share | 9.15 | 1.04 | 5.21 | |
| Share holders equity per share | 10.71 | 6.98 | 10.99 | |
| Interest debt per share | 2.91 | 5.17 | 3.61 | |
| Market cap | 624.26M | 1.96B | 1.35B | |
| Enterprise value | 654.43M | 2.07B | 1.34B | |
| P/E ratio | -10.39 | -17.08 | -8.79 | |
| Price to sales ratio | 4.03 | 10.4 | 5.57 | |
| POCF ratio | -19.4 | -75.13 | -58.23 | |
| PFCF ratio | -17.09 | -57.91 | -33.48 | |
| P/B Ratio | 3.11 | 7.11 | 2.58 | |
| PTB ratio | 3.11 | 7.11 | 2.58 | |
| EV to sales | 4.22 | 10.94 | 5.54 | |
| Enterprise value over EBITDA | -14.71 | -24.04 | -9.65 | |
| EV to operating cash flow | -20.33 | -78.98 | -58 | |
| EV to free cash flow | -17.92 | -60.88 | -33.35 | |
| Earnings yield | -0.1 | -0.06 | -0.11 | |
| Free cash flow yield | -0.06 | -0.02 | -0.03 | |
| Debt to equity | 0.24 | 0.61 | 0.35 | |
| Debt to assets | 0.34 | 0.55 | 0.37 | |
| Net debt to EBITDA | -0.68 | -1.17 | 0.04 | |
| Current ratio | 5.48 | 3.75 | 5.46 | |
| Interest coverage | -8.76 | -8.31 | 8.73 | |
| Income quality | 0.54 | 0.23 | 0.15 | |
| Dividend Yield | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.2 | 0.31 | 0.36 | |
| Research and developement to revenue | 0.3 | 0.28 | 0.26 | |
| Intangibles to total assets | 0.1 | 0.38 | 0.33 | |
| Capex to operating cash flow | 0.13 | 0.3 | 0.74 | |
| Capex to revenue | -0.03 | -0.04 | -0.07 | |
| Capex to depreciation | -0.47 | -0.42 | -0.46 | |
| Stock based compensation to revenue | 0.12 | 0.2 | 0.27 | |
| Graham number | 27.79 | 21.38 | 28.25 | |
| ROIC | -0.22 | -0.21 | -0.19 | |
| Return on tangible assets | -0.22 | -0.34 | -0.27 | |
| Graham Net | 7.86 | 0.14 | 3.61 | |
| Working capital | 216.02M | 241.76M | 415.34M | |
| Tangible asset value | 171.42M | 41.02M | 247.34M | |
| Net current asset value | 162.52M | 28.16M | 198.39M | |
| Invested capital | 0.24 | 0.7 | 0.36 | |
| Average receivables | 37.93M | 48.3M | 48.55M | |
| Average payables | 4.48M | 5.33M | 5.01M | |
| Average inventory | 0 | 0 | 0 | |
| Days sales outstanding | 64.95 | 93.35 | 73.63 | |
| Days payables outstanding | 17.55 | 19.84 | 13.77 | |
| Days of inventory on hand | 0 | 0 | 0 | |
| Receivables turnover | 5.62 | 3.91 | 4.96 | |
| Payables turnover | 20.8 | 18.39 | 26.5 | |
| Inventory turnover | 0 | 0 | 0 | |
| ROE | -0.3 | -0.42 | -0.29 | |
| Capex per share | -0.23 | -0.2 | -0.36 |
Quarterly Fundamentals Overview
Last date of statement is 2022-06-30 for Q2
| Metric | History | 2021-06-30 | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 1.33 | 1.26 | 1.24 | 1.28 | 1.32 | |
| Net income per share | -0.8 | -0.82 | -0.94 | -0.42 | -0.62 | |
| Operating cash flow per share | -0.11 | -0.11 | -0.19 | 0.02 | -0.18 | |
| Free cash flow per share | -0.19 | -0.19 | -0.23 | -0.06 | -0.24 | |
| Cash per share | 5.85 | 9.29 | 8.54 | 8.03 | 7.51 | |
| Book value per share | 6.15 | 11.21 | 10.02 | 9.07 | 8.74 | |
| Tangible book value per share | 1.83 | 5.43 | 4.75 | 3.55 | 3.23 | |
| Share holders equity per share | 6.15 | 11.21 | 10.02 | 9.07 | 8.74 | |
| Interest debt per share | 4.54 | 4.22 | 3.52 | 4.72 | 4.65 | |
| Market cap | 2.49B | 2.45B | 2.06B | 1.39B | 777.75M | |
| Enterprise value | 2.49B | 2.38B | 2.06B | 1.44B | 849.18M | |
| P/E ratio | -17.38 | -15.31 | -10.54 | -15.42 | -5.82 | |
| Price to sales ratio | 41.79 | 39.69 | 31.91 | 20.34 | 11.01 | |
| POCF ratio | -514.27 | -457.17 | -211.24 | 1.2K | -81.22 | |
| PFCF ratio | -296.06 | -264.14 | -170.2 | -474.01 | -59.46 | |
| P/B Ratio | 9.03 | 4.46 | 3.95 | 2.88 | 1.66 | |
| PTB ratio | 9.03 | 4.46 | 3.95 | 2.88 | 1.66 | |
| EV to sales | 41.7 | 38.5 | 31.82 | 21.08 | 12.02 | |
| Enterprise value over EBITDA | -104.82 | -75.31 | -48.35 | -114.31 | 257.09 | |
| EV to operating cash flow | -513.15 | -443.42 | -210.68 | 1.24K | -88.68 | |
| EV to free cash flow | -295.41 | -256.2 | -169.75 | -491.14 | -64.92 | |
| Earnings yield | -0.01 | -0.02 | -0.02 | -0.02 | -0.04 | |
| Free cash flow yield | 0 | 0 | -0.01 | 0 | -0.02 | |
| Debt to equity | 0.08 | 0.04 | 0.35 | 0.51 | 0.52 | |
| Debt to assets | 0.51 | 0.35 | 0.37 | 0.42 | 0.42 | |
| Net debt to EBITDA | 0.23 | 2.33 | 0.13 | -3.99 | 21.63 | |
| Current ratio | 1.26 | 1.96 | 5.46 | 5.21 | 5.15 | |
| Interest coverage | -7.75 | -9.47 | 10.23 | -13.49 | -28.13 | |
| Income quality | 0.14 | 0.13 | 0.2 | -0.05 | 0.29 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.38 | 0.37 | 0.39 | 0.13 | 0.25 | |
| Research and developement to revenue | 0.24 | 0.27 | 0.27 | 0.25 | 0.26 | |
| Intangibles to total assets | 0.34 | 0.34 | 0.33 | 0.35 | 0.36 | |
| Capex to operating cash flow | 0.74 | 0.73 | 0.24 | -3.52 | 0.37 | |
| Capex to revenue | -0.06 | -0.06 | -0.04 | -0.06 | -0.05 | |
| Capex to depreciation | -0.44 | -0.37 | -0.22 | -0.35 | -0.27 | |
| Stock based compensation to revenue | 0.3 | 0.28 | 0.25 | 0.27 | 0.25 | |
| Graham number | 10.51 | 14.35 | 14.56 | 9.3 | 11.07 | |
| ROIC | -0.1 | -0.07 | -0.06 | -0.03 | -0.05 | |
| Return on tangible assets | -0.1 | -0.07 | -0.09 | -0.04 | -0.06 | |
| Graham Net | 0.24 | 3.97 | 3.29 | 2.14 | 1.8 | |
| Working capital | 66.46M | 251.97M | 415.34M | 389.84M | 375.06M | |
| Tangible asset value | 82.17M | 265.96M | 247.34M | 188.4M | 173.57M | |
| Net current asset value | 34M | 219.03M | 198.39M | 138.48M | 123.09M | |
| Invested capital | 0.72 | 0.37 | 0.36 | 0.52 | 0.53 | |
| Average receivables | 44.8M | 45.15M | 45.71M | 42.63M | 45.19M | |
| Average payables | 5.56M | 5.32M | 5.28M | 5.87M | 5.78M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 70.9 | 69.51 | 67.87 | 56.35 | 60.85 | |
| Days payables outstanding | 15.75 | 12.98 | 12.47 | 15.53 | 9.28 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 1.27 | 1.29 | 1.33 | 1.6 | 1.48 | |
| Payables turnover | 5.71 | 6.93 | 7.22 | 5.8 | 9.7 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.13 | -0.07 | -0.09 | -0.05 | -0.07 | |
| Capex per share | -0.08 | -0.08 | -0.05 | -0.08 | -0.07 |
Company Profile
- Volume Average 1.08M
- Market Capitalization 621.11M
- Employee 1.2K
- CEO Mr. Daniel D. Burton
- Headquarters Salt Lake City,UTAH,US
- IPO Date 2019-07-25
-
Website
https://www.healthcatalyst.com 
Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations. Its offerings include data and analytics platform, a commercial-grade data and analytics platform for the healthcare sector; AI and data science, providing integration of AI into existing business intelligence tools, increasing analytics accuracy; population health management identifies improvement across the care continuum as well as actionable guidance for success and automated workflows; financial transformation providing costing and labor productivity insights and revenue capture; quality and safety improvement using clinical quality and patient safety data, analytics, and expert services; and national data ecosystem for thought leadership and mutual knowledge exchange to transform care delivery through next-gen insights. The company was formerly known as HQC Holdings, Inc. and changed its name to Health Catalyst, Inc. in March 2017. Health Catalyst, Inc. was founded in 2008 and is based in South Jordan, Utah.
